Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Immunoregulation with levamisole

  • 49 Accesses

  • 27 Citations

Summary

Levamisole, a simple synthetic chemical, was first introduced as an anthelmintic in human and veterinary medicine. The drug is the first member of a potential new class of immunologically active, possibly thymomimetic compounds. It seems to regulate cell mediated immune reactions by restoring effector functions of peripheral T-lymphocytes and phagocytes and by stimulating precursor T-lymphocytes to differentiate into mature cells. It shares these effects with a number of other immune regulators.

Levamisole was tested in a large number of diseases with suspected immune imbalance. The drug is of therapeutic benefit in certain recurrent and chronic infections where it reduces the frequency, duration, and severity of disease episodes, in recurrent or chronic inflammatory diseases, such as rheumatoid arthritis where it reduces disease activity and delays progression, and in cancer where it prolongs remission and survival following successful cytoreductive therapy.

Its possible mode of action is discussed.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Aceves, J., Erlij, D., Marlinez-Maranon, R.: The mechanism of the paralyzing action of tetramisole on Ascaris somatic muscle. Br. J. Pharmacol. 38, 602 (1970)

  2. 2.

    Allen, D. E., Kaplan, B., Pinnell, S. R.: Levamisole and skin disease. Int. J. Dermatol. 17, (4), 287 (1978)

  3. 3.

    Amery, W. K., Verhaegen, H.: Effects of levamisole treatment in cancer patients. J. Rheumatol. 5 (suppl. 4), 123 (1978)

  4. 4.

    Anderson, R., Glover, A., Koornhof, H. J., Rabson, P.: In vitro stimulation of neutrophil motility by levamisole. Maintenance of COMP levels in chemotactically stimulated levamisole treated neutrophils. J. Immunol. 117, 428 (1976)

  5. 5.

    Arias, I. M., Jakoby, W. B.: Glutathione: metabolism and function. New York: Raven Press 1976

  6. 6.

    Armerding, D., Katz, D. H.: Activation of T- and B-lymphocytes in vitro. IV. Regulatory influences on specific T-cell functions by a thymus extract factor. J. Immunol. 114, 1248 (1975)

  7. 7.

    Bach, J.-F., Dardenne, M., Papiernik, M., Barois, A., Levasseur, Ph., Le Brigand, H.: Evidence for a serum factor secreted by the human thymus. Lancet 1972 II, 1056

  8. 8.

    Bach, J.-F., Dardenne, M., Salomon, J.-C.: Studies on thymus products. IV. Absence of serum thymic activity in adult NSB and (NZB × NZW) F1 mice. Clin. Exp. Immunol. 14, 247 (1973)

  9. 9.

    Baehner, R. L., Boxer, L. A., Allen, J. M., Davis, J.: Auto-oxidation as a basis for altered function by polymorphonuclear leukocytes. Blood 50, 327 (1977)

  10. 10.

    Basch, R. S., Goldstein, G.: Antigenic and functional evidence for the in vitro inductive activity of thymopoietin (thymin) on thymocyte precursors. Ann. N. Y. Acad. Sci. 249, 290 (1975)

  11. 11.

    Benediktov, I. I.: Effect of anthelmintics on metabolism of Fasciola hepatica. Med. Parazitol. (Mosk) 43, 700 (1974)

  12. 12.

    Bertrand, J., Renoux, G., Renoux, M., Palat, A.: Maladie de Crohn et lévamisole. Nouv. Presse Méd. 3 (35), 2265 (1974)

  13. 13.

    Bliznakov, E. G., Wan, Y.-P., Chang, D., Folkers, K.: Partial reactivation of impaired immune competence in aged mice by synthetic thymus factors. Biochem. Biophys. Res. Commun. 80, 631 (1978)

  14. 14.

    Bourne, H. R., Lehrer, R. I., Clein, M. J., Melmon, K. L.: Cyclic 3′, 5′-adenosine monophosphate in the human leukocyte: synthesis, degradation, and effects of neutrophil candidacidal activity J. Clin. Invest. 50, 920 (1971)

  15. 15.

    Broome, J. D., Jeng, M. W.: Promotion of replication in lymphoid cells by specific thiols and disulfides in vitro. J. Exp. Med. 138, 574 (1973)

  16. 16.

    Bryant, R. E., Sutcliffe, M.: The effect of cyclic AMP on granulocyte adhesiveness. Clin. Res. 21, 594 (1973)

  17. 17.

    Ceglowski, W. S.: Effects of immunoactive substances on murine virus leukenogenesis and immunosuppression. In: Modulation of host immune resistance in the prevention or treatment of induced neoplasias, Chirigos, M. A., ed., p. 287. Fogarty International Center Proceedings No. 28, Washington: U. S. Government Printing Office 1977

  18. 18.

    Chadwick, R. G., Jain, S., Thomas, H. C., Sherlock, S.: Levamisole in the treatment of HBS antigen positive chronic active liver disease. Gut 18, A979 (1977)

  19. 19.

    Charreire, J., Bach, J.-F.: The effect of thymic hormones on autologous rosette forming cells. In: Biological activity of thymic hormones, Van Bekkum, D. W., ed., p. 245. Rotterdam: Kooyker Scientific Publications 1975

  20. 20.

    Chirigos, M. A., Pearson, J. W., Fuhrman, F. S.: Effect of tumor load reduction on successful immunostimulation. Proc. Am. Assoc. Cancer Res. 15, 116 (1974)

  21. 21.

    Coles, G. C., East, J. M., Jenkins, S. M.: The mode of action of four anthelmintics. Experienta 30, 1265 (1974)

  22. 22.

    Coles, G. C., East, J. M., Jenkins, S. M.: The mechanism of action of the anthelmintic levamisole. Gen. Pharmacol. 6, 309 (1975)

  23. 23.

    Colpaert, F. C., Lenaerts, F. M., Niemegeers, C. J. E., Janssen, P. A. J.: A critical study on Ro-4–1284 antagonism in mice. Arch. Int. Pharmacodyn. Ther. 215, 40 (1975)

  24. 24.

    Dardenne, M., Bach, J. F.: Studies on thymus products. I. Modification of rosette forming cells by thymic extracts. Determination of the target RFC subpopulation. Immunology 25, 343 (1973)

  25. 25.

    De Cock, W., De Cree, J., Verhaegen, H.: Restoration by levamisole of histamine inhibited E-rosette formation of T-lymphocytes of patients with allergies. Int. Arch. Allergy Appl. Immunol. 54, 176 (1977)

  26. 26.

    De Cock, W., De Cree, J., Verhaegen, H.: Restoration by levamisole of histamine, db-cAMP and adenosin inhibited E-rosette forming cells. J. Immunopharm. (in press)

  27. 27.

    De Cree, J., Verhaegen, H., De Cock, W., Verbruggen, F.: A randomized double-blind trial of levamisole in the therapy of recurrent aphthous stomatitis. Oral Surg. 45, 378 (1978)

  28. 28.

    De Meyer, J., Degraeve, M., Clarysse, J., Deloose, F., Peremans, W.: Levamisole in aphthous stomatitis: evaluation of three regimens. Br. Med. J. 1, 671 (1977)

  29. 29.

    DeRubertis, F. R., Zenser, T. V., Adler, W. H., Hudson, T.: Role of cyclic adenosine 3′, 5′-monophosphate in lymphocyte mitogenesis. J. Immunol. 113, 151 (1974)

  30. 30.

    Editorial: Malfunctioning and microtubules. Lancet 1978 I, 697

  31. 31.

    Estensen, R. D., Hill, H. R., Quie, P. G., Hogan, N., Goldberg, N. D.: Cyclic GMP and cell movement. Nature 245, 458 (1973)

  32. 32.

    Fauve, R. M.: Immunologie — Immunorépulsion. C. R. Acad. Sci. [D] (Paris) 282, 1207 (1976)

  33. 33.

    Ferreira, G. G. R., Massuda Brascher, H. K., Javierre, M. Q., Sassine, W. A., Lima, A. O.: Rosette formation by human T- and B-lymphocytes in the presence of adrenergic and cholinergic drugs. Experientia 32, 1594 (1976)

  34. 34.

    Fischer, G. W., Crumrine, M. H., Balk, M. W., Chang, S. P., Hokama, Y.: Levamisole: a synthetic agent with thymosin-like activity (abstract). Pediatr. Res. 10 (4), 386 (1976)

  35. 35.

    Florentin, I., Bruley-Rosset, M., Davigny, M.: Effects of acute versus chronic administration of BCG in young and aged mice. Cancer Immunol. Immunother. 3 (1), 33 (1977)

  36. 36.

    Forbes, L. S.: Toxicological and pharmacological relations between levamisole, pyrantel and diethylcarbamzine and their significance in helminth chemotherapy. Southeast Asian J. Trop. Med. Public. Health. 3, 235 (1972)

  37. 37.

    Galant, S. P., Rome, R. A.: β-adrenergic inhibition of human T-lymphocyte rosettes. J. Immunol. 114, 512 (1975)

  38. 38.

    Galant, S. P., Lundak, R. L., Eaton, L.: Enhancement of early human E-rosette formation by cholinergic stimuli. J. Immunol. 117, 48 (1976)

  39. 39.

    Goebel, K. M., Goebel, F. D., Schubotz, R., Hahn, E., Neurath, F.: Levamisole-induced immunostimulation in spondylarthropaties. Lancet 1977 II, 214

  40. 40.

    Goldstein, G., Scheid, M., Boyse, E. A., Brand, A., Gilmour, D. G.: Thymopoietin and bursapoietin induction signals regulating early lymphocyte differentiation. Cold Spring Harbor Symp. Quant. Biol. 41, 5 (1977)

  41. 41.

    Goldstein, G.: Mode of action of levamisole. J. Rheumatol. 5 (suppl. 4), 143 (1978)

  42. 42.

    Gordon, B. L., Keenan, J. P.: The treatment of systemic lupus erythematosus (SLE) with the T-cell immunostimulant drug levamisole: a case report. Ann. Allergy 35, 343 (1975)

  43. 43.

    Gordon, B. L., Yanagihara, R.: Treatment of systemic lupus erythematosus with the T-cell immunopotentiator levamisole: a follow-up report of 16 patients under treatment for a minimum period of four months. Ann. Allergy 39 (4), 227 (1977)

  44. 44.

    Graziani, G., De Martin, G. L.: Pharmacokinetic studies on levamisole: absorption, distribution, excretion and metabolism of levamisole in animals, a review. Drugs Exp. Clin. Res. 2, 221 (1977)

  45. 45.

    Graziani, G., De Martin, G. L.: Pharmacokinetic studies on levamisole: on the pharmacokinetics and relative bioavailability of levamisole in man. Drugs Exp. Clin. Res. 2, 235 (1977)

  46. 46.

    Griscelli, C., Prieur, A. M., Da Guillard, F.: Levamisole therapy in congenital immunodeficiencies. In: Immune modulation and control of neoplasia by adjuvant therapy, Chirigos, M. A., ed., p. 165. New York: Raven Press 1978

  47. 47.

    Hadden, J. W., Coffey, R. G., Hadden, E. M., Lopez-Corrales, E., Sunshine, G. H.: Effects of levamisole and imidazole on lymphocyte proliferation and cyclic nucleotide levels. Cell. Immunol. 20, 98 (1975)

  48. 48.

    Hadden, J. W.: Levamisole, cyclic nucleotides, and immunopharmacology. In: Modulation of host immune resistance in the prevention or treatment of induced neoplasias, Chirigos, M. A., ed., p. 353. Fogarty International Center Proceedings No. 28, Washington: U. S. Government Printing Office 1977

  49. 49.

    Haneke, E., Meinhof, W.: Levamisol zur Behandlung therapieresistenter Follikulitiden. Z. Hautkr. 52 (13), 688 (1977)

  50. 50.

    Harman, D., Heidrick, M. L., Eddy, D. E.: Free radical theory of aging: effect of free-radical-reaction inhibitors on the immune response. J. Am. Geriatr. Soc. 25, 400 (1977)

  51. 51.

    Hashimoto, K., Miki, T., Kazuta, Y., Horiuchi, A.: The effect of levamisole on the natural history of New Zealand mice. Allergy 27 (7), 617 (1978)

  52. 52.

    Hatch, G. E., Nichols, W. K., Hill, H.: Cyclic nucleotide changes in human neutrophils induced by chemo-attractants and chemotactic modulators. J. Immunol. 119, 450 (1977)

  53. 53.

    Hersey, P.: Recent views on tomuor antigens and their relation to host defence mechanisms. Aust. NZ. J. Med. 7, 526 (1977)

  54. 54.

    Hogan, N. A., Hill, H. R.: Enhancement of neutrophil chemotaxis and alteration of levels of cellular cyclic nucleotides by levamisole. J. Infect. Dis. 138, 437 (1978)

  55. 55.

    Ignarro, L. J., Cech, S. Y.: Bidirectional regulation of lysosomal enzyme secretion and phagocytosis in human neutrophils by guanosine 3′, 5′-monophosphate and adenosine 3′, 5′-monophosphate (39232). Proc. Soc. Exp. Biol. Med. 151, 448 (1976)

  56. 56.

    Ikehara, S., Hamashima, Y., Masuda, T.: Immunological restoration of both thymectomized and athymic nude mice by a thymus factor. Nature 258, 335 (1975)

  57. 57.

    Ippen, H., Quadripur, S. A.: Levamisol zur Behandlung von Hautkrankheiten. Dtsch. Med. Wochenschr. 100, 1710 (1975)

  58. 58.

    Ivanyi, L., Lehner, T.: The effect of levamisole on gingival inflammation in man. Scand. J. Immunol. 6, 219 (1977)

  59. 59.

    Janssen, P. A. J.: Recent advances in the treatment of parasitic infections in man. In: Progress research, Jucker, E., ed., Vol. 18, p. 191. Basel: Birkhauser Verlag 1974

  60. 60.

    Janssen, P. A. J.: The levamisole story. In: Progress research, Jucker, E., ed., Vol. 20, p. 347. Basel: Birkhauser Verlag 1976

  61. 61.

    Jarish, R., Sandor, I.: MIF in der Therapiekontrolle von Herpes Simplex recidivans: Behandlung mit Levamisole, BCG, Urushiol und Herpes Antigen Vaccine. Arch. Dermatol. Res. 258, 151 (1977)

  62. 62

    Kagan, W. A., O'Neill, G. J., Incefy, G. S., Goldstein, G., Good, R. A.: Induction of human granulocyte differentiation in vitro by ubiquitin and thymopoietin. Blood 50, 275 (1977)

  63. 63.

    Kazura, J., Guerry, D., Negendank, W., Cooper, R. A., Schreiber, A. D.: Human monocytelymphocyte interaction mediated by concanavalin A: the effect of levamisole. In: Regulatory mechanisms in lymphocyte activation, Lucas, D. O., ed., p. 722. New York: Academic Press 1977

  64. 64.

    Klassen, L. W., Budman, D. R., Williams, D. R., Williams, G. W., Steinberg, A. D., Gerber, N. L.: Ribavirin: efficacy in the treatment of murine autoimmune disease. Science 195, 787 (1977)

  65. 65.

    Kook, A. I., Trainin, N.: Intracellular events involved in the induction of immune competence in lymphoid cells by a thymus humoral factor. J. Immunol. 114, 151 (1975)

  66. 66.

    Koopman, W. J., Gillis, M. H., David, J. R.: Prevention of MIF activity by agents known to increase cellular cyclic AMP. J. Immunol. 110, 1609 (1973)

  67. 67.

    Kurland, J. I., Hadden, J. W., Moore, M. A. S.: Role of cyclic nucleotides in the proliferation of committed granulocyte-macrophage progenitor cells. Cancer Res. 37, 4534 (1977)

  68. 68.

    Lehner, T., Wilton, J. M. A., Ivanyi, L.: Double blind crossover trial of levamisole in recurrent aphthous ulceration. Lancet 1976 II, 926

  69. 69.

    Lichtenstein, L. M., Henney, C. S., Bourne, H. R., Greenough, W. B.: Effect of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3′, 5′-monophosphate. J. Clin. Invest. 52, 691 (1973)

  70. 70.

    Mahmood, T., Robinson, W. A.: Effect of levamisole on human granulopoiesis in vitro. Proc. Soc. Exp. Biol. Med. 156, 359 (1977)

  71. 71.

    Martinez, D., Zaias, N.: Levamisole as adjunct to dapsone in leprosy. Lancet 1976 II, 209

  72. 72.

    Marx, J. L.: Thymic hormones: inducers of T cell maturation. Science 187, 1183 (1975)

  73. 73.

    Merluzzi, V. J., Kaiser, C. W., Cooperband, S. R.: Differential effects of levamisole on murine lymphoid tissues (abstract). Fed. Proc. 35 (3), 334 (1976)

  74. 74.

    Michalevicz, R., Many, A., Ramot, B., Trainin, N.: The in vitro effect of thymic humoral factor and levamisole on peripheral blood lymphocytes in systemic lupus erythematosus patients. Clin. Exp. Immunol. 31, 111 (1978)

  75. 75.

    Molin, L., Stendahl, O.: Enhancing effect of levamisole on the phagocytic activity of human neutrophil polymorphonuclear leucocytes in vitro. Scand. J. Haematol. 19, 93 (1977)

  76. 76.

    Mowat, A. G.: Neutrophil chemotaxis in rheumatoid arthritis. Effect of d-penicillamine, gold salts and levamisole. Ann. Rheum. Dis. 37, 1 (1978)

  77. 77.

    Multicenter Study Group (Vischer, T. L., Veys, E., Symoens, J., Rosenthal, M., Huskisson, E. C., et al.): Levamisole in rheumatoid arthritis. A multicenter randomized double-blind study comparing two dosage schedules of levamisole and placebo. Lancet 1978 II, 1007 (1978)

  78. 78.

    Multicenter Study Group: A multicenter randomized double-blind study comparing two dosages of levamisole in rheumatoid arthritis. J. Rheumatol. 5 (suppl. 4), 5 (1978)

  79. 79.

    Natarajan, P. N., Zaman, V., Yeoh, T. S.: In vitro activity of levamisole in the infective larvae, microfilariae and adult worms of Breinlia sergenti. Int. J. Parasitol. 4, 207 (1971)

  80. 80.

    Nathanson, S. D., Zamfirescu, P. L., Dekernion, J.: Acute changes in monocyte motility following oral levamisole (abstract). J. Reticuloendothel. Soc. 22, suppl. 18A (1977)

  81. 81.

    Nogueira Machada, J. A., Jones Antunes, L., Novato Silva, E.: E-rosette formation in ‘active’ T-lymphocytes: phenomenon modulated by the intracellular level of cyclic AMP and GMP. Rev. Bras Pesqui Med. Biol. 10 (4), 241 (1977)

  82. 82.

    Oliveira Lima, A., Javierre, M. G., Dias da Silva, W., Sette Camara, D.: Immunological phagocytosis: effect of drugs on phosphodiesterase activity. Experientia 30, 945 (1974)

  83. 83.

    O'Reilly, R. J., Chibbaro, A., Wilmot, R., Lopez, C. Correlation of clinical and virus-specific immune responses following levamisole therapy of recurrent herpes progenitalis. Ann. N. Y. Acad. Sci. 284, 161 (1977)

  84. 84.

    Oshita, A. K., Rothstein, G., Lonngi, G.: cGMP stimulation of stem cell proliferation. Blood 49, 585 (1977)

  85. 85.

    Par, A., Barna, K., Hollos, I., Kovacs, M., Miszlai, Zs., Patakfalvi, A., Javor, T.: Levamisole in viral hepatitis. Lancet 1977 I, 702 (1977)

  86. 86.

    Persico, F. J., Potter, W. A.: The effect of levamisole on an in vitro model of cellular immunity. In: Immune modulation and control of neoplasia by adjuvant therapy, Chirigos, M. A., ed., p. 85. New York: Raven Press 1978

  87. 87.

    Rabson, A. R., Anderson, R., Glover, A.: Defective neutrophil movement. In vitro and in vivo effects of levamisole (abstract). Ann. Allergy 38 (4), 308 (1977)

  88. 88.

    Raeymaekers, A. H. M., Allewijn, F. T. N., Vandenberk, J., Demoen, P. J. A., Van Offenwert, T. T. T., Janssen, P. A. J.: Novel broad-spectrum anthelmintics. Tetramisole and related derivatives of 6-arylimidazo [2,1-b] thiazole. J. Med. Chem. 9, 545 (1966)

  89. 89.

    Ramot, B., Biniaminov, M., Shoham, Ch., Rosenthal, E.: The effect of levamisole on E-rosette-forming cells in vivo and in vitro in Hodgkin's disease patients. N. Engl. J. Med. 294, 809 (1976)

  90. 90.

    Renoux, G., Renoux, M.: Effet immunostimulant d'un imidothiazole dans l'immunisation des souris contre l'infection par Brucella abortus. C. R. Acad. Sci. [D] (Paris) 272, 349 (1971)

  91. 91.

    Renoux, G., Renoux, M.: Immunopotentiation par les thiols et disulfures. C. R. Acad. Sci. [D] (Paris) 278, 1139 (1974)

  92. 92.

    Renoux, G., Renoux, M.: Mécanismes d'action du lévamisole, stimulant des réponses d'immunité cellulaire. Ann. Immunol. (Paris) 128 C, 275 (1977)

  93. 93.

    Renoux, G., Renoux, M.: Roles of the imidazole or thiol moiety on the immunostimulant action of levamisole. In: Control of neoplasia by modulation of the immune system, Chirigos, M. A., ed., p. 67. New York: Raven Press 1977

  94. 94.

    Renoux, G., Renoux, M.: Thymus-like activities of sulphur derivates on T-cell differentiation. J. Exp. Med. 145, 466 (1977)

  95. 95.

    Romanowski, R. D., Rhoads, M. L., Colglazier, M. L., Kates, K. C.: Effect on combendazole, thiabendazole and levamisole on fumarate reductase in combendazole-resistant and -sensitive strains of Haemonchus contortus. J. Parasitol. 61, 777 (1975)

  96. 96.

    Rosenthal, M., Trabert, U., Müller, W.: Immunotherapy with levamisole in rheumatic diseases. Scand. J. Rheumatol. 5, 216 (1976)

  97. 97.

    Russell, A. S.: Therapeutic trials with levamisole and other agents in NZB/W mice. J. Rheumatol. 3, 380 (1976)

  98. 98.

    Saint-André, P., Louvet, M.: Stimulation de l'immunité cellulaire dans la lépre lépromateuse par lévamisole. Méd. Armées 4 (3), 223 (1976)

  99. 99.

    Scheid, M. P., Hoffmann, M. K., Komuro, K., Hämmerling, U., Abbott, J., Boyse, E. A., Cohen, G. H., Hooper, J. A., Schulof, R. S., Goldstein, A. L.: Differentiation of T-cells induced by preparations from thymus and by nonthymic agents. J. Exp. Med. 138, 1027 (1973)

  100. 100.

    Scheid, M. P., Goldstein, G., Boyse, E. A.: Differentiation of T-cells in nude mice. Science 190, 1211 (1975)

  101. 101.

    Schreiner, G. F., Unanue, E. R.: The modulation of spontaneous and anti-Ig-stimulated motility of lymphocytes by cyclic nucleotides and adrenergic and cholinergic agents. J. Immunol. 114, 802 (1975)

  102. 102.

    Schwab, J. H.: Suppression of the immune response by microorganisms. Bacteriol. Rev. 39, 121 (1975)

  103. 103.

    Segal, A. W., Levi, A. J., Loewi, G.: Levamisole in the treatment of Crohn's disease. Lancet 1977 II, 382

  104. 104.

    Soppi, E., Fräki, J., Eskola, J., Ruuskanen, O.: Effect of levamisole on the maturation of guinea pig thymocytes. Clin. Immunol. Immunopathol. 11, 318 (1978)

  105. 105.

    Ström, T. B., Carpenter, C. B., Garovoy, M. R., Austen, K. F., Merrill, J. P., Kaliner, M.: The modulating influence of cyclic nucleotides upon lymphocyte-mediated cytotoxicity. J. Exp. Med. 138, 381 (1973)

  106. 106.

    Sunshine, G., Lopez-Corrales, E., Hadden, E. M., Coffey, R. G., Wanebo, H., Hadden, J. W., Rojas, A.: Levamisole and imidazole: in vitro effects in mouse and man and their possible mediation by cyclic nucleotides. In: Modulation of host immune resistance in the prevention or treatment of induced neoplasias, Chirigos, M. A., ed., p. 31. Fogarty International Center Proceedings No. 28, Washington: U. S. Government Printing Office 1977

  107. 107.

    Sunshine, G. H., Basch, R. S., Coffey, R. G., Cohen, K. W., Goldstein, G., Hadden, J. W.: Thymopoietin enhances the allogeneic response and cyclic GMP levels of mouse peripheral, thymus-derived lymphocytes. J. Immunol. 120, 1594 (1978)

  108. 108.

    Symoens, J., Rosenthal, M.: Levamisole in the modulation of the immune response: the current experimental and clinical state. J. Reticuloendothel. Soc. 21, 175 (1977)

  109. 109.

    Symoens, J., Veys, E., Mielants, M., Pinals, R.: Adverse reactions to levamisole. Cancer Treat. Rep. (in press)

  110. 110.

    Talal, N., Dauphinee, M., Pillarisetty, R., Goldblum, R.: Effect of thymosin on thymocyte proliferation and autoimmunity in NZB mice. Ann. N. Y. Acad. Sci. 249, 438 (1975)

  111. 111.

    Thienpont, D., Vanparijs, O. F. J., Raeymaekers, A. H. M., Vandenberk, J., Demoen, P. J. A., Allewijn, F. T. N., Marsboom, R. P. H., Niemegeers, C. J. E., Schellekens, K. H. L., Janssen, P. A. J.: Tetramisole (R 8299) a new potent broad spectrum anthelminticum. Nature 209, 1084 (1966)

  112. 112.

    Thornes, R. D.: The anergy of chronic human brucellosis. J. Irish Med. Assoc. 70 (16), 480 (1977)

  113. 113.

    Van Belle, H.: Kinetics and inhibition of alkaline phosphatases from canine tissues. Biochim. Biophys. Acta 289, 158 (1972)

  114. 114.

    Urist, M. M., Boddie, A. W., Townsend, C. M., Holmes, E. C.: In vitro evidence for increased cellular immunity to lung cancer antigen during levamisole immunotherapy. J. Thorac. Cardiovasc. Surg. 73 (2), 189 (1977)

  115. 115.

    Van de Heyning, J.: Levamisole in the treatment of recurrent aphthous stomatitis. Laryngoscope 88 (3), 522 (1978)

  116. 116.

    Van den Bossche, H., Janssen, P. A. J.: The biochemical mechanism of action of the antinematodal drug tetramisole. Biochem. Pharmacol. 18, 35 (1969)

  117. 117.

    Van Eygen, M., Znamensky, P. Y., Heck, E., Raymaekers, I.: Levamisole in prevention of recurrent upper-respiratory tract infections in children. Lancet 1976 I, 382

  118. 118.

    Van Ginckel, R. F., Hoebeke, J.: Carbon clearance enhancing factor in serum for levamisole treated mice. J. Reticuloendothel. Soc. 17 (2), 65 (1975)

  119. 119.

    Van Ginckel, R., Hoebeke, J.: Effect of levamisole on spontaneous rosette-forming cells in murine spleen. Eur. J. Immunol. 6, 305 (1976)

  120. 120.

    Van Ginckel, R., De Brabander, M.: The influence of a levamisole metabolite/dl-2-oxo-3-(2-mercaptoethyl)-5-phenylimidazolidine/on carbon clearance in mice. J. Reticuloendothel. Soc. (in press)

  121. 121.

    Vanhoutte, P. M., Van Nueten, J. M., Verbeuzen, T. J., Laduron, P. M.: Differential aspects of the isomers of tetramisole on adrenergic neurotransmission in cutaneous veins of the dog. J. Pharmacol. Exp. Ther. 200, 127 (1977)

  122. 122.

    Van Nueten, J. M.: Pharmacological aspects of tetramisole. In: Comparative biochemistry of parasites, Van den Bossche, H., ed., p. 101. New York: Academic Press 1972

  123. 123.

    Van Wauwe, J., Van Nijen, G.: Effect of levamisole on autologous rosette-forming cells in nude mice. Clin. Exp. Immunol. 30, 465 (1977)

  124. 124.

    Varsano, I., Danon, Y., Jaber, L., Livni, E., Shohat, B., Yakir, Y., Shneyour, A., Trainin, N.: Reconstitution of T-cell function in patients with subacute sclerosing panencephalitis treated with thymus humoral factor. Isr. J. Med. Sci. 12, 1168 (1976)

  125. 125.

    Wang, E. J., Saz, H. J.: Comparative biochemical studies of Litomosoides carinii, Dipetalonema viteae and Brugia pahangi adults. J. Parasitol. 60, 316 (1974)

  126. 126.

    Wara, D. W., Goldstein, A. L., Doyle, N. E., Ammann, A. J.: Thymosin activity in patients with cellular immunodeficiency. N. Engl. J. Med. 292, 70 (1975)

  127. 127.

    Watson, J., Epstein, R., Cohn, M.: Cyclic nucleotides as intracellular mediators of the expression of antigen-sensitive cells. Nature 246, 405 (1973)

  128. 128.

    Watson, J.: The influence of intracellular levels of cyclic nucleotides on cell proliferation and the induction of antibody synthesis. J. Exp. Med. 141, 97 (1975)

  129. 129.

    Weinstein, Y., Chambers, D. A., Bourne, H. R., Melmon, K. L.: Cyclic GMP stimulates lymphocyte nucleic acid synthesis. Nature 251, 352 (1974)

  130. 130.

    Willoughby, D. A., Wood, C.: The history and development of levamisole. Forum on Immunotherapy, Royal Society of Medicine 1, 1 (1977)

  131. 131.

    Willoughby, D. A., Wood, C.: Levamisole in cancer. Forum of Immunotherapy, Royal Society of Medicine 2, 1 (1978)

  132. 132.

    Windil, R., Wood, R. F. M., Bell, P. F. R.: Reduction of the duration of postoperative immunosuppression by levamisole. Br. J. Surg. 65, 355 (1978)

  133. 133.

    Woods, W. A., Papas, T. S., Chirigos, M. A.: The effect of levamisole on in vitro parameters of the immune response. In: Modulation of host immune resistance in the prevention or treatment of induced neoplasias, Chirigos, M. A., ed., p. 23. Fogarty International Center Proceedings No. 28, Washington: U. S. Government Printing Office 1977

  134. 134.

    Wright, D. G., Kirkpatrick, C. H., Gallin, J. I.: Effects of levamisole on normal and abnormal leukocyte locomotion. J. Clin. Invest. 59, 941 (1977)

  135. 135.

    Wybran, J., Govaerts, A.: Levamisole and human lymphocyte surface markers. Clin. Exp. Immunol. 27, 319 (1977)

  136. 136.

    Zaizov, R., Vogel, R., Cohen, I., Varsano, I., Shohat, B., Rotter, V., Trainin, N.: Thymic hormone (THF) therapy in immunosuppressed children with lymphoproliferative neoplasia and generalized varicella. Biomedicine 27, 105 (1977)

  137. 137.

    Zulman, J., Michalski, J., McCombs, C., Greenspan, J., Talal, N.: Levamisole maintains cyclophosphamide-induced remission in murine lupus erythematosus. Clin. Exp. Immunol. 31, 321 (1978)

Unpublished Reports

  1. 138.

    Abad, M., Chang, S., Hokama, Y.: The effect of levamisole on spleen peroxisomal enzymes and DNA synthesis in rats of different age groups (abstract). Presented at the Annual Xavier-MBS Biomedical Symposium, Xavier University, New Orleans, Louisiana, April 1976

  2. 139.

    De Brabander, M., Aerts, F., Geuens, G., Van de Veire, R., Van Belle, H.: O. M. P. I. A. sulfhydryl metabolite of levamisole that interacts with microtubules. Chem. Biol. Interact. 23, 45 (1978)

  3. 140.

    De Brabander, M., Van Belle, H., Aerts, F., Van de Veire, R., Geuens, G.: Protective effect of levamisole and its sulfhydryl metabolite OMPI against cell death induced by glutathione depletion. Unpublished report, August 1978

  4. 141.

    De Brabander, M., Van Belle, H., Aerts, F., Van Ginckel, R., Geuens, G., Van de Veire, R.: Levamisole, sulfhydryls and microtubules: possible clues to the mechanism of its immunomodulating activity. Unpublished report, August 1978

  5. 142.

    De Cock, W., Van der Veken, L., De Cree, J., Verhaegen, H.: The in vitro effects of levamisole and thymopoietin pentapeptide on the phagocytosis and chemotaxis of polymorphonuclear neutrophils (PMN) of healthy subjects. Unpublished clinical research report on levamisole, No. 70, January 1978

  6. 143.

    De Cree, J., Verhaegen, H., De Cock, W., Brugmans, J.: Australia antigen and immunity. The effect of levamisole on the clinical and immunological features of Australia antigen (HbAA) patients from a psychiatric institution. Communication presented at the Memorial Sloan-Kettering Cancer Center, New York, November 1973

  7. 144.

    De Cree, J., Verhaegen, H., De Cock, W.: Treatment of 6 cases of recurrent infections by levamisole. Unpublished clinical research report on levamisole, No. 23, March 1975

  8. 145.

    De Loore, F., Heck, E., Van Eygen, M., Gasneuf, J.: Levamisole (R 12 564) in the prevention of recurrent upper respiratory tract infections in children. A double-blind placebo-controlled study. Unpublished clinical research report on levamisole, No. 85, July 1978

  9. 146.

    Diamantstein, T.: Einfluß von Levamisol auf immunologische Funktionen. Unpublished data, September 1973

  10. 147.

    Dils, F.: A double-blind placebo-controlled study of levamisole (R 12 564) in children with recurrent infections of the upper respiratory tract. Unpublished clinical research report on levamisole, No. 84, June 1978

  11. 148.

    Di Perri, T., Auteri, A., Laghi Pasini, L., Mattioloi, F., Volpi, L.: Action of levamisole on the E-rosette forming cells and plasmatic adenosine deaminase in Hodgkin's disease. J. Immunopharmacol. (in press, 1979)

  12. 149.

    Di Perri, T.: Comparison of the ‘in vitro’ effects of thymopoietin pentapeptide and levamisole on E-rosette forming cells. Preliminary study. Unpublished report, July 1978

  13. 150.

    Gonsette, R., Demonty, L., Delmotte, P., De Cree, J., De Cock, W., Verhaegen, H., Symoens, J.: Levamisole therapy in patients with multiple sclerosis. Interim evaluation of a double-blind placebo-controlled study. Unpublished clinical research report on levamisole, No. 61, September 1977

  14. 151.

    Hadden, J. W., Englard, A., Sadlik, J. R., Hadden, E. M.: The comparative effects of isoprinosine, levamisole, muramyl dipeptide and SM 1213 on lymphocyte and macrophage proliferation and activation in vitro. Unpublished report, June 1978

  15. 152.

    Kalmar, L., Gergely, P., Gonzalez, C. R., Lang, I., Nekam, K.: Effect of levamisole on cyclic nucleotide contents of human lymphocytes and PHA-induced blast transformation. Unpublished report, August 1978

  16. 153.

    Kaslik, J., Vanek, I., Haskova, V., Hatala, M.: Treatment of chronic infections with levamisole in patients with phagocyte mechanism disturbances (abstract). Presented at the 4th European Immunology Meeting, Budapest (Hungary) April 12–14, 1978

  17. 154.

    Kromer, K.: The influence of levamisole on the duration of an influenza outbreak: a double-blind placebo-controlled study. Unpublished clinical research report on levamisole, No. 65, August 1977

  18. 155.

    Lehner, T., Wilton, J. M. A.: In vivo and in vitro effect of levamisole on lymphocytes from patients with Behet's syndrome and recurrent oral ulceration. Unpublished report, May 1978

  19. 156.

    Lewinski, U., Mavligit, G. M., Thompson, W. J., Hersh, E. M., Ortez, R. A.: Immunotherapy with levamisole: early decrease of CAMP levels in lymphocytes from treated cancer patients. Unpublished report, April 1977

  20. 157.

    Padarathsingh, M. L., Dean, J. H., McCoy, J. L., Lewis, D. D., Morthing, J. W.: Restorative effects of levamisole on cell-mediated immune responses following chemotherapy with aniline mustard in mice bearing adj-pcs plasmacytoma. Unpublished report, May 1978

  21. 158.

    Renoux, G., Renoux, M., Kassel, R. L., Fiore, N. C.: Genetic and epigenetic factors modulate immunostimulation by levamisole in normal and leukemic mice. Evidences for a serum transfer. Unpublished report, August 1976

  22. 159.

    Van Ginckel, R.: Effects of a serum factor from levamisole treated mice on spontaneous rosette-forming cells in the murine spleen. Unpublished preclinical research report on levamisole, No. 2, June 1976

  23. 160.

    Verhaegen, H., De Cock, W., De Cree, J., Goldstein, G.: Comparison of the in vitro effects of thymopoietin pentapeptide and levamisole on peripheral E-rosette forming cells. Unpublished report, August 1978

  24. 161.

    Vogler, C., Morris, A. D., Mierzwa, P., Moeschberger, M.: Immunostimulation therapy of lupus erythematosus (SLE): effect of levamisole on NZB/NZW nephritis (abstract). Annual Meeting of the Midwest Section of the AFCR Immunology-Rheumatology Section, November 1976

  25. 162.

    Wallace, A. M.: The effects of levamisole on the anti-DNA antibody response of NZB/NZW mice. Unpublished data, March 1977

  26. 163.

    Weksler, M. E., Innes, J. B., Goldstein, G.: Immunological studies of aging. IV. The contribution of thymic involution to the immune deficiencies of aging mice and reversal with thymopoietin32–36. J. Exp. Med. 148, 996 (1978)

Download references

Author information

Correspondence to J. Symoens.

Additional information

An extensive description of the immunotherapeutic experience with levamisole is being published in: ‘Drug Profiles: pharmacological and biochemical considerations’, M. E. Goldberg, ed., APhA Academy of Pharmaceutical Sciences, Pharmacology and Toxicology Section (to be published early in 1979)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Symoens, J., Rosenthal, M., De Brabander, M. et al. Immunoregulation with levamisole. Springer Semin Immunopathol 2, 49–68 (1979). https://doi.org/10.1007/BF00201973

Download citation

Keywords

  • Rheumatoid Arthritis
  • Immune Reaction
  • Arthritis
  • Inflammatory Disease
  • Veterinary Medicine